MONTREAL, Nov. 22, 2017 /CNW/ - The Health Research Foundation (HRF) of Innovative Medicines Canada, along with Prix Galien
These awards recognize and celebrate the best and brightest minds and discoveries in the Canadian
Key highlights include:
The winners of this year's awards are:
HRF Medal of Honour
Dr. Ian Stiell - Dr. Stiell is a clinical epidemiologist and an emergency medicine physician whose focus on health services research in emergency medicine has had a direct impact on countless lives in Canada and abroad. He leads the Ottawa Hospital Emergency Medicine Research Group. His research has changed the way emergency room doctors across the world diagnose certain patients. Dr. Stiell obtained his Doctor of Medicine degree from the University of Western Ontario in 1975, and his Master of Science (Epidemiology), from the University of Ottawa in 1991. He has published 302 peer-reviewed papers in high-impact journals and has won many international awards that include election into the U.S. Institute of Medicine.
Research Canada Leadership in Advocacy Award
Dr. Eleanor Fish and Dr. Christopher Paige - Both winners were chosen based on their impact on advancing health research through their advocacy efforts. Dr. Fish has had a tremendous impact through the media by helping Canadians understand the benefits of Canadian health research to their everyday lives. Dr. Paige has built partnerships and promoted health research and health innovation policies through a number of organizations and institutions with which he has been affiliated, and, in some cases, created.
Prix Galien Canada Research Award
Dr. Ernesto Schiffrin - Dr. Schiffrin is one of Canada's most outstanding clinician scientists whose bench to bedside insights into the mechanisms and therapy of hypertension have had a transformative effect on our understanding and management of cardiovascular disease. His laboratory has elucidated the differential beneficial effects of ACE inhibitors, angiotension receptor antagonists, mineralocorticoid receptor blockers and calcium channel antagonists on vascular structure and endothelial function in essential hypertension and diabetes.
Prix Galien Canada Innovative Product Award
The Prix Galien Canada - Innovative Product Award was given to Merck Canada Inc. for Pembrolizumab (Keytruda) which is a highly selective humanized anti-programmed cell death receptor antibody that restores T-cell mediated immune response against different types of cancer cells including advanced non-small cell lung cancer. The research and development of this drug involved two Canadian principal investigators, authorship on significant publications, partnership with six reference laboratories across the country to provide standardized PD-L1 testing, and enrollment of over 100 patients in 25 clinical trial centres.
About the Health Research Foundation of Innovative Medicines Canada
The Health Research Foundation (HRF) is a non-profit organization whose mission is to support and promote the value of health research in Canada. By applying the highest standards of scientific excellence, addressing health system sustainability challenges and establishing partnerships, the HRF, one of the leading private health research foundations in the country, contributes significantly to the prevention and treatment of disease, to a better health care system and the availability for Canadians to access effective health products.
About The Prix Galien
The Prix Galien is the most prestigious award in the field of Canadian pharmaceutical research and innovation. Referred to as the Nobel Prize of pharmaceutical research, it recognizes the efforts and achievements of pharmaceutical research and development. The Prix Galien Canada is organized by Innovation Life Canada, a non-profit organization whose mission is to celebrate Canadian innovation in the life sciences.
About Research Canada
Research Canada: An Alliance for Health Discovery, is a national, broad-based alliance dedicated to increasing investments in health research through collaborative advocacy. We believe health research is a shared benefit, shared responsibility and an investment in Canada's future. We engage government, academia, industry and non-profit sectors to build support for balanced and long-term health research funding investments that strengthen Canada's innovation system and lead to better health, sustainable health care, new commercialization opportunities, and skilled jobs for Canadians. Only through sustained and balanced investments in health research will Canada succeed in keeping its citizens the healthiest and most prosperous in the world.
SOURCE Health Research Foundation
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All